P4 Outcome Following Switch Between Brand Name And Generic Tacrolimus In Paediatric Population
January 2018
in “
Archives of Disease in Childhood
”
TLDR Switching to generic tacrolimus was safe, effective, and saved money.
The study evaluated the clinical outcomes of switching 36 paediatric patients from the brand name tacrolimus (Prograf) to its generic counterpart (Adoport) at Nottingham Children’s Renal Unit. The switch was monitored by reviewing Tacrolimus levels and clinical variations in immunosuppression before and after the switch. Results showed that most patients tolerated the switch well, with stable Tacrolimus levels and no significant changes in creatinine levels. Only one patient experienced hair loss and requested to revert to Prograf, and one patient required a dose adjustment. The switch resulted in cost savings for NHS England, supporting the use of Adoport as a cost-effective alternative to Prograf.
